OverviewSuggest Edit
CureVac is a biotechnology company that is active in the field of messenger RNA (mRNA) technology. Using mRNA it is able to directly give the body the information it needs to fight disease. CureVac mainly focuses on three therapeutic areas: cancer immunotherapies, prophylactic vaccines, and protein delivery.
| Type | Private | |
| Founded | 2000 | |
| HQ | Tübingen, DE | Map |
| Website | curevac.com |
Recent NewsAll News
- CureVac stock gains after upbeat preclinical data on COVID-19 vaccine candidate on primates
- Thinking about trading options or stock in CureVac, Coinbase, Advanced Micro Devices, Moderna, or AMC Entertainment?
- Stocks making the biggest moves in the premarket: Walgreens, Didi, CureVac & more
- CureVac to 'plow forward' with Covid vaccine despite disappointing results
Key People/Management at CureVac
Ingmar Hoerr
Franz-Werner Haas
Florian von der Mulbe
Pierre Kemula
Mariola Fotin-Mleczek
Igor Splawski
CureVac Office Locations
CureVac Financials and Metrics
Summary Metrics
Founding Date | 2000 |
CureVac total Funding | $1.1 b |
CureVac latest funding size | $640 m |
Time since last funding | a year ago |
CureVac investors | Qatar Investment Authority, Baillie Gifford, DH Capital, Bill & Melinda Gates Foundation, OH Beteiligungen, dievini Hopp Biotech Holding, Baden-Württembergische Versorgungsanstalt für Ärzte, Chartwave, Coppel Family, Landeskreditbank Baden-Württemberg, LBBW Asset Management, Northview LifeSciences, Sigma Group, The European Commission |
CureVac Revenue
| EUR | |
|---|---|
Revenue (FY, 2018) | 12.6m |
Revenue growth (FY, 2017 - FY, 2018), % | 92.1% |
Gross profit (FY, 2018) | (9.8m) |
Gross profit margin (FY, 2018), % | (78%) |
Net income (FY, 2018) | (74.6m) |
Market valuation | 1.5b |
Cash (31-Dec-2018) | 60.9m |
EV | 1.4b |
| EUR | FY, 2016 |
|---|---|
Revenue/Employee | 85.3k |
Debt/Equity | 0.1 x |
Financial Leverage | 1.4 x |
CureVac Acquisitions / Subsidiaries
| Company Name | Date | Deal Size |
|---|---|---|
| CureVac Inc. | ||
| CureVac Real Estate GmbH |
CureVac Revenue Breakdown
CureVac revenue breakdown by business segment: 37.3% from Goods Deliveries and 62.7% from Services
CureVac revenue breakdown by geographic segment: 78.3% from Foreign and 21.7% from Germany
CureVac Cybersecurity Score
CureVac Online and Social Media Presence
5 Twitter followers
CureVac has 5 Twitter Followers. The number of followers has increased 344.4% quarter over quarter
CureVac's Trends
CureVac News and Updates
CureVac stock gains after upbeat preclinical data on COVID-19 vaccine candidate on primates
Thinking about trading options or stock in CureVac, Coinbase, Advanced Micro Devices, Moderna, or AMC Entertainment?
Stocks making the biggest moves in the premarket: Walgreens, Didi, CureVac & more
CureVac to 'plow forward' with Covid vaccine despite disappointing results
The Wall Street Journal: CureVac says COVID-19 vaccine was 48% effective in key study
CureVac Drops After Full Data Show Covid Vaccine Trails Rivals
CureVac Blogs
[English only] CureVac Announces Voting Results of General Meeting
[English only] Celonic and CureVac Announce Agreement to Manufacture over 100 Million Doses of CureVac’s COVID-19 Vaccine Candidate, CVnCoV
CureVac Frequently Asked Questions
When was CureVac founded?
CureVac was founded in 2000.
Who are CureVac key executives?
CureVac's key executives are Ingmar Hoerr, Franz-Werner Haas and Florian von der Mulbe.
How many employees does CureVac have?
CureVac has 400 employees.
What is CureVac revenue?
Latest CureVac annual revenue is €12.6 m.
What is CureVac revenue per employee?
Latest CureVac revenue per employee is €31.4 k.
Who are CureVac competitors?
Competitors of CureVac include Stemirna, RNACure and RNAimmune.
Where is CureVac headquarters?
CureVac headquarters is located at Friedrich-Miescher-Straße 15, Tübingen.
Where are CureVac offices?
CureVac has offices in Tübingen, Frankfurt am Main and Boston.
How many offices does CureVac have?
CureVac has 4 offices.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies